Inherited BRCA mutations may affect CDK4/6 treatment outcomes

https://www.facingourrisk.org/XRAY/brca-mutations-cdk4-6-inhibitor-outcomes

Several studies suggest that people with an inherited BRCA1 or BRCA2 mutation and hormone receptor-positive, HER2-negative breast cancer may have a shorter response to CDK4/6 inhibitors than people without these mutations. (posted 10/21/2026)

By: Piri Welcsh, PhD
Reviewed by: Allison Kurian, MD, MSc

Questions To Ask Your Health Care Provider

What are my treatment options, and would (or do) genetic testing results contribute to selecting my best options?
If I am taking a CDK4/6 inhibitor, how will we know whether it is working?
Am I eligible for other treatments such as a PARP inhibitor?

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.